| Field | Specification |
|---|---|
| Mfr No | |
| Activity | |
| Cas No. | |
| Concentration | |
| Form | Lyophilized powder. |
| Product Type | |
| Purity | |
| Reconstitution | |
| Shipping | |
| Solubility | 40 mM in DMSO. Centrifuge all product preparations before use (10000 x g for 1 min). |
| Source | Synthetic |
| Storage | |
| Target |
Product details
- Chemical name: (Z)-1-(3-(3-((1H-pyrrol-2-yl)methylene)-2-oxoindolin-6-ylamino)-4-methylphenyl)-3-(2-fluoro-5-(trifluoromethyl)phenyl)urea.
- CAS number: 1033769-28-6
- Molecular formula: C28H21F4N5O2.
- Purity: >95%
- Concentration: 1 nM - 10 µM.
- Form: Lyophilized powder.
- Solubility: 40 mM in DMSO. Centrifuge all product preparations before use (10000 x g for 1 min).
- Reconstitution: 40 mM in DMSO. Centrifuge all product preparations before use (10000 x g for 1 min).
- Shipping: Shipped at room temperature. Product as supplied can be stored intact at room temperature for several weeks. For longer periods, it should be stored at -20°C.
- Target: TrkA, TrkB, TrkC receptors
- Source: Synthetic
- Activity: GNF 5837 displays antiproliferative effects in cellular Ba/F3 assays (IC50 values are 7, 9 and 11 nM for cells containing the fusion proteins Tel-TrkC, Tel-TrkB and Tel-TrkA, respectively)1.
Scientific background
Three tropomyosin-related kinase (TrkA, TrkB, and TrkC) receptors bind the following neurotrophic factors with varied affinities: nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), neurotrophin-3 (NT-3), and neurotrophin-4 (NT-4); BDNF and NT-4 activate TrkB, while NGF and NT-3 activate TrkA and TrkC; NT-3 also activates the other two TRKs, albeit more weakly. After ligand binding, TRKs form dimers, and the subsequent kinase activation results in transphosphorylation of tyrosine residues which in turn enable the binding of cytoplasmic proteins that exhibit phosphotyrosine-binding (PTB) or Src-homology-2 (SH2) domains, such as phospholipase C (PLC-gamma1), p85 and Shc1-3.GNF-5837 is a novel oxindole urea inhibitor of TRKs. With exceptional binding affinity to TrkA, TrkB, and TrkC (IC50 = 0.011, 0.009, and 0.007 μM/L, respectively), GNF-5837 is a pan-TRK inhibitor that has enhanced selectivity for TRKs, and demonstrates efficiency in mammalian models of tumor. Many carcinomas - not necessarily nerve tissue-related - involve TRK signaling by NTs; GNF-5837 can therefore have useful application in cancer research in addition to other of its many other uses in many biological research branches4,5.
Lead time: 1-2 Business Days
Country of origin: Israel/IL
Applications key
Application key: FC- Flow cytometry, IFC- Indirect flow cytometry, IHC- Immunohistochemistry,LCI- Live cell imaging, Calcium imaging assay,Cell survival assay, Electrophysiology, Neurite outgrowth assay.
Bioassay tested: Yes
Need this compound in a format that drops straight into your assay? We can tailor formulation, chemistry, and documentation so your results stay consistent across runs and re-orders.
- Format options: solid or pre-dissolved solution (choose solvent), target concentration, aliquots, light/moisture-protected packaging
- Chemistry options: free base/acid vs salt forms, hydrate/solvate preference, stereoisomer control (single enantiomer or racemate), close analogs
- Add-on labels & handles: D/¹³C/¹⁵N isotopes (LC-MS/internal standards), azide/alkyne or other functional handles for conjugation
- QC & documentation: standard COA or enhanced analytical pack (HPLC/LC-MS/NMR), chiral purity, residual solvents, water content (KF), method-specific specs
- Scale & continuity: mg to gram scale, bulk pricing, lot reservation, repeat-order continuity
To quote quickly, tell us: compound name + CAS/structure (SMILES or mol file), intended assay context, solvent preference, salt/stereochemistry requirements, purity/QC level, and the amount (mg–g).
Can’t find the compound you’re looking for?
Send the CAS or structure and your specs. We can help source it, suggest close equivalents, or discuss custom synthesis with the right QC documentation (RUO).
